Literature DB >> 27916470

Is There Evidence for the Presence and Relevance of the PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an Immunohistochemical Study.

Matthias Troeltzsch1, Timothy Woodlock2, Alix Pianka3, Sven Otto4, Markus Troeltzsch5, Michael Ehrenfeld6, Thomas Knösel7.   

Abstract

PURPOSE: To examine oral squamous cell carcinoma (OSCC) specimens for programmed death ligand-1 (PD-L1) expression and presence of programmed death-1 (PD-1)-positive tumor-infiltrating lymphocytes (TILs) and to determine possible clinicopathologic implications. It was hypothesized that PD-L1 expression and PD-1-positive TIL presence in OSCC would have no clinical relevance.
MATERIALS AND METHODS: The authors implemented a retrospective cohort study design. The study cohort was chosen in compliance with predefined inclusion criteria. Demographic, clinical, and histopathologic data were gathered. Tissue microarrays were obtained from paraffin-embedded OSCC specimens and analyzed immunohistochemically for PD-L1 expression and PD-1-positive TIL infiltration. PD-L1 positivity of OSCC specimens served as the predictor variable and neck node metastasis served as the primary outcome variable. Descriptive and inferential statistics were computed and the significance level was set at a P value less than or equal to .05.
RESULTS: The study sample was composed of 88 patients (48 men, 40 women; mean age, 61.34 yr). Marked PD-L1 expression was detected in 29% of OSCC specimens (26 of 88) and 83% of specimens (73 of 88) exhibited a high rate of PD-1-positive TIL infiltration. PD-L1 positivity of OSCC samples was significantly associated with the anatomic origin of OSCC (P = .039), presence of cervical metastasis (P = .039), and high PD-L1-positive TIL infiltration (P = .033).
CONCLUSION: A considerable proportion of OSCCs exhibited marked PD-L1 expression. This could be associated with clinical parameters. PD-L1 expression in OSCC might differ depending on its anatomic origin. PD-1-positive TILs could be detected in most OSCC specimens. These findings might indicate a potential role for the PD-1 and PD-L1 pathway in OSCC.
Copyright © 2016 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27916470     DOI: 10.1016/j.joms.2016.11.006

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  12 in total

Review 1.  Molecular Insights into Oral Malignancy.

Authors:  Anuja Deshmukh; Karthik Nagaraja Rao; Ripu Daman Arora; Nitin M Nagarkar; Ambesh Singh; Om Shree Shetty
Journal:  Indian J Surg Oncol       Date:  2021-09-11

2.  Galectin 3 expression in regional lymph nodes and lymph node metastases of oral squamous cell carcinomas.

Authors:  Falk Wehrhan; Maike Büttner-Herold; Luitpold Distel; Jutta Ries; Patrick Moebius; Raimund Preidl; Carol I Geppert; Friedrich W Neukam; Marco Kesting; Manuel Weber
Journal:  BMC Cancer       Date:  2018-08-16       Impact factor: 4.430

3.  Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma.

Authors:  Vinícius Gonçalves de Souza; Damilys Joelly Souza Santos; Ana Gabriela Silva; Rosy Iara Maciel de Azambuja Ribeiro; Adriano Mota Loyola; Sérgio Vitorino Cardoso; Carla Silva Siqueira Miranda; Ludimila Paula Vaz Cardoso
Journal:  J Appl Oral Sci       Date:  2022-02-21       Impact factor: 2.698

4.  Low PDL1 Expression in Tumour Infiltrating Lymphocytes Predicts Local Recurrence in Oral Squamous Cell Carcinoma.

Authors:  Narayana Subramaniam; Ajit Nambiar; Sujan Dhar; Krishnakumar Thankappan; Manzoor Koyakutty; Deepak Balasubramanian; Manjula Das; Subramania Iyer
Journal:  Indian J Surg Oncol       Date:  2021-04-27

5.  PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma.

Authors:  Manuel Weber; Falk Wehrhan; Christoph Baran; Abbas Agaimy; Maike Büttner-Herold; Raimund Preidl; Friedrich W Neukam; Jutta Ries
Journal:  Oncotarget       Date:  2017-11-08

6.  Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4.

Authors:  Shinji Yamada; Shunsuke Itai; Mika K Kaneko; Yukinari Kato
Journal:  Biochem Biophys Rep       Date:  2018-02-06

7.  Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study.

Authors:  Kanan Dave; Aiman Ali; Marco Magalhaes
Journal:  Sci Rep       Date:  2020-06-16       Impact factor: 4.379

8.  High PD-L1 expression in the tumour cells did not correlate with poor prognosis of patients suffering for oral squamous cells carcinoma: A meta-analysis of the literature.

Authors:  Giuseppe Troiano; Vito C A Caponio; Khrystyna Zhurakivska; Claudia Arena; Giuseppe Pannone; Marco Mascitti; Andrea Santarelli; Lorenzo Lo Muzio
Journal:  Cell Prolif       Date:  2018-11-15       Impact factor: 6.831

9.  Clinicopathological Features of Programmed Cell Death-ligand 1 Expression in Patients with Oral Squamous Cell Carcinoma.

Authors:  Yong-Xin Cui; Xian-Shuang Su
Journal:  Open Med (Wars)       Date:  2020-04-17

10.  Prognosis Value of Immunoregulatory Molecules in Oral Cancer Microenvironment: An Immunohistochemical Study.

Authors:  Juan Francisco Peña-Cardelles; José Juan Pozo-Kreilinger; Giovanna Roncador; Jesús Esteban-Hernández; José Ernesto Moro-Rodríguez; Ana Sastre-Perona; Beatriz Castelo-Fernández; José Luis Cebrián-Carretero
Journal:  Biomedicines       Date:  2022-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.